Management of hypertension before, during, and after pregnancy

Heart

Volumn 90, Issue 12, 2004, Pages 1499-1504

  James, P Rachael ^b   Nelson Piercy, Catherine ^a,c  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b ROYAL SUSSEX COUNTY HOSPITAL   (United Kingdom)

^c GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; HYDRALAZINE; LABETALOL; MAGNESIUM SULFATE; METHYLDOPA; NIFEDIPINE; OXPRENOLOL; PRAZOSIN; STEROID; THIAZIDE DIURETIC AGENT;

BLOOD PRESSURE MEASUREMENT; CHRONIC DISEASE; CLINICAL TRIAL; COLOR ULTRASOUND FLOWMETRY; CONGENITAL MALFORMATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ECLAMPSIA; FEMALE; FETUS LUNG MATURATION; FETUS MONITORING; HEMOLYTIC ANEMIA; HUMAN; HYPERTENSION; HYPOTENSION; INTRAUTERINE GROWTH RETARDATION; JOINT CONTRACTURE; KIDNEY FAILURE; KIDNEY TUBULE DISORDER; LIVER TOXICITY; LUNG HYPOPLASIA; MATERNAL CARE; MATERNAL HYPERTENSION; META ANALYSIS; OLIGOHYDRAMNIOS; PATIENT COUNSELING; PLACENTA CIRCULATION; PLASMA VOLUME; PRACTICE GUIDELINE; PREECLAMPSIA; PREGNANCY; PRIORITY JOURNAL; PUERPERAL DEPRESSION; RECURRENT DISEASE; REVIEW; RISK FACTOR; SEIZURE; SKULL MALFORMATION; STEROID THERAPY; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TREATMENT INDICATION; UTERINE ARTERY;

ANTIHYPERTENSIVE AGENTS; CHRONIC DISEASE; COUNSELING; ECLAMPSIA; FEMALE; HUMANS; HYPERTENSION; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PRENATAL CARE; RISK FACTORS;

EID: 10344264445     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2004.035444     Document Type: Review

References (28)

1. Sibai BM. Treatment of hypertension in pregnancy. N Engl J Med 1996;335:257-65. Excellent review article of the management of hypertension in pregnancy.
2. Shennan A, Gupta M, Halligan A, et al. Lock of reproducibility in pregnancy of Korotkoff phase IV measured by mercury sphygmomanometry. Lancet 1996;347:139-42. A well conducted trial evaluating the identification and reproducibility of Korotkoff sounds IV and V in pregnancy.
3. Brown MA, Reiter L, Smith B, et al. Measuring blood pressure in pregnant women: a comparison of direct and indirect methods. Am J Obstet Gynecol 1994;171:661-7.
4. Magee LA, Ornstein MP, von Dadelszen P. Management of hypertension in pregnancy. BMJ 1999;318:1332-6.
5. Brown MA, Hague WM, Higgins J, et al. The detection, investigation and management or hypertension in pregnancy: full consensus statement. Ausf N Z J Obstet Gynaecol 2000;40:139-55. Good overview of pregnancy induced hypertension, including drug treatment.
6. McCowan LME, Buist RG, North RA, et al. Perinatal morbidity in chronic hypertension. Br J Obstet Gynaecol 1996;103:123-9.
7. Walker JJ. Pre-eclampsia. Lancet 2000;356:1260-5. A broad overview of the epidemiology, pothophysiology, and management of pre-eclampsia.
8. Soudan P, Brown MA, Buddle ML, et al. Does gestational hypertension become pre-eclampsia? Br J Obstet Gynaecol 1998;105:1177-84.
9. Broughton Pipkin F. Risk factors far pre-eclampsia. N Engl J Med 2001;344:925-6. An excellent editorial on the multiple risk factors for developing pre-eclampsia.
10. Royal College of Obstetricians and Gynaecologists. Confidential enquiry into maternal deaths in the United Kingdom. Why mothers die. London: Royal College of Obstetricians and Gynaecologists, 2001. Death from cardiac disease is now the joint most common cause of maternal death in the UK. This latest report is highly informative.
11. Roberts J. Endothelial dysfunction in preeclampsia. Semin Reprod Endocrinol 1998;16:5-15.
12. Roberts JM, Hubel CA. Is oxidative stress the link in the two-stage model of pre-eclampsia? Lancet 1999;354:788-9.
13. Dekker GA, Sibai BM. Etiology and pathogenesis of preeclampsia: current concepts. Am J Obstet Gynecol 1998;179:1359-75.
14. Caritis S, Sibai BM, Hauth J, et al. Low-dose aspirin to prevent pre-eclampsia in women at risk. N Engl J Med 1998;338:701-5.
15. Chappell LC, Seed PT, Briley AL, et al. Effects of antioxidants on the occurrence of pre-eclampsia in women at increased risk: a randomised trial. Lancet 1999;354:810-16.
16. Von Dadelszen P, Omstein MP, Bull SB, et al. Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: a meta-analysis. Lancet 2000;355:87-92.
17. Homuth V, Dechend R, Luft FC. When should pregnant women with an elevated blood pressure be treated? Nephrol Dial Transplant 2003;18:1456-7. An up to date evaluation of the evidence for treatment of hypertension in pregnancy.
18. Cockburn J, Moar VA, Ounsted M, et al. Final report of study on hypertension during pregnancy: the effects of specific treatment on the growth and development of the children. Lancet 1982;i:647-9.
19. Briggs GG, Freeman RK, Yaffe SJ. In Mitchell CW, ed. Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk, 6th ed. Philadelphia: Lippincott Williams and Wilkins, 2002. A comprehensive, up to date text, solely on the safety of drugs in pregnancy and breastfeeding.
20. Committee on Drugs, American Academy of Pediatrics. The transfer of drugs and other chemicals into human milk. Pediatrics 1994;93:137-50.
21. Hargpod JL, Brown MA. Pregnancy-induced hypertension; recurrence rate in second pregnancies. Med J Austral 1991;154:376-87.
22. Zhang J, Troendle JF, Levine RJ. Risks of hypertensive disorders in the second pregnancy. Paediatr Perinat Epidemiol 2001;15:226-31.
23. Wilson BJ, Watson MS, Prescott GJ, et al. Hypertensive diseases of pregnancy and risk of hypertension and stroke in later fire: results from cohort study. BMJ 2003;326:845-9.
24. Smith GCS, Pell JP, Walsh D. Pregnancy complications and maternal complications of ischaemic heart disease: a retrospective cohort study of 129 290 births. Lancet 2001;357:2002-6.
25. Hannaford P, Ferry S, Hirsh S. Cardiovascular sequelae of toxaemia of pregnancy. Heart 1997;77:154-8.
26. Jonsdattir LS, Arnsgrimsson R, Geirsson RT, et al. Death rates from ischemic heart disease in women with a history of hypertension in pregnancy. Acta Obstet Gynecol Scand 1995;74:772-6.
27. Chambers JC, Fusi L, Malik IS, et al. Association of maternal endothelial dysfunction with preeclampsia. JAMA 2001;258:1607-12.
28. Seely EW. Hypertension in pregnancy: a potential window into long-term cardiovascular risk in women. Clin Endo Metab 1999;84:1858-61. An overview of possible mechanisms involved in the increased cardiovascular risk in women with a prior history of pregnancy induced hypertension.